NASDAQ:ANTX
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. reported net income of −$35.2M in fiscal 2025. The diluted share count rose 1.3%.Summary generated from AN2 Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−52.1%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+1.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −22 | −42 | −70 | −57 | −38 |
| Net income | −22 | −41 | −65 | −51 | −35 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 16, 2026 - 4Insider transaction report
Sep 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KResults of a shareholder vote
Jun 9, 2026 - 8-KRegulation FD disclosure
Jun 4, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 11, 2026 - 8-KResults of operations and financial condition
May 11, 2026